Loading summary
Transcript6 lines
- [00:01]
A
This episode is brought to you by Rumchata, a delicious creamy blend of horchata with rum. It's best enjoyed over ice or in your coffee. Rumchata Delivering vacation vibes anyway, or anywhere you drink it. Find out more@rumchata.com drink responsibly Caribbean rum with real dairy cream, natural and artificial flavors. Alcohol 13.75% by volume 27.5 proof Copyright 2025 Agave Loco Brands, Pojoaquee, Wisconsin. All rights reserved.
- [00:34]
B
When did making plans get this complicated? It's time to streamline with WhatsApp, the secure messaging app that brings the whole group together. Use polls to settle dinner plans, send event invites and pin messages so no one forgets mom 60th and never miss a meme or milestone. All protected with end to end encryption. It's time for WhatsApp message privately with everyone.
- [00:57]
C
Learn more@WhatsApp.com Running a business comes with a lot of what ifs, but luckily there's a simple answer to them. Shopify it's the commerce platform behind millions of businesses including Thrive Cosmetics and Momofuku, and it'll help you with everything you need. From website design and marketing to boosting sales and expanding operations. Shopify can get the job done and make your dream a reality. Turn those what ifs into Sign up for your $1 per month trial@shopify.com specialoffer.
- [01:30]
D
I'm Scott Galloway and this is no mercy, no malice. America has become a giant bet on AI. A better bet. GLP1America's best bet as read by George Ha.
- [01:55]
E
America is now one giant bet on AI. If not for the magnificent 10, the markets would be flat for the year. There's a different technology that offers more asymmetric upside. If we want to transform the economy and the well being of Americans, we should focus on GLP1, not GPT5. More than 40% of American adults, 100 million people are struggling with obesity. By 2060, half of US adults may be obese. The health care costs of all that extra weight could exceed $20 trillion over that period. Our debt, $5 trillion in receipts versus $7 trillion in spending has become the IED of our economy. We don't know when or why it will detonate if we're going to have an adult conversation regarding spending, all roads lead to the same place. Healthcare. We spend $13,000 per person versus $6,500 in the rest of the G7. Matching the efficiency of our peers would save us $2 trillion a year. Why do we spend Double to die sooner while experiencing more anxiety, depression and chronic illness. Our problem isn't vaccines, food dyes or Tylenol. It's fat. The Milken Institute and McKinsey have estimated that obesity costs us about 400 billion doll indirect medical costs and lost productivity. US healthcare isn't about caring for health. It's about monetizing it. Just as Big Tech found the gangster app for shareholder value rage, the industrial food, hospital and pharma complexes have found obesity. They get you addicted to sugar and salt, then hand you to the non health complex for replacements, dialysis and statins. They've even rebranded disease as identity. You're not obese. You're living your truth. No, you're finding diabetes. McDonald's and Coca Cola celebrate obesity so UnitedHealthcare can monetize it. These stocks aren't equities, they're obesity indices. We know exercise, healthier food and less screen time help, but they're not enough. The good news? Obesity may have peaked in the US and we have the tools to actually reverse it. Pushing for a radically lower price and rolling out weight loss drugs to tens of millions of Americans could be revolutionary, possibly the best civic investment in recent history. In sum, our instincts have not kept pace with industrial production and and we gorge. GLP1s put scaffolding on our instincts. Most of us have friends or colleagues we barely recognize after they've taken novel weight loss drugs. By mimicking a hormone called GLP1. The medicines suppress hunger and make us feel fuller, longer. The results are dramatic. 15% to 20% reductions in body weight. Yet uptake remains small relative to the tens of millions who could benefit. Coverage is patchy. Only 30% to 40% of commercial plans and 14 state Medicaid programs cover the cost of GLP1s for obesity. The administration is considering a pilot to expand coverage under Medicaid and Medicare. A shift in policy after rejecting a Biden era plan that would have cost $35 billion over 10 years. Prices need to fall for the math to work. If Medicare began covering GLP1s, researchers estimate 3 million beneficiaries would start using them over the next decade at a gross cost of $66 billion and savings in avoiding health care spending of $18 billion for a net price tag of 48 billion. Costs are moving in the right direction. Wegovy and Ozempic now run under $7,000 a year. Costco offers a monthly supply of obesity drugs for $499, and competition from Lilly and others is driving prices down more than 100 next generation obesity drugs are in development, including pill versions. President Trump on October 16th vowed to slash GLP1 prices to $150 a month to match the expense in other developed nations. But no deal yet exists with drug makers. Investors, however, took him seriously. Shares of Novo Nordisk and Lilly dropped sharply on the news. Economist Emily Oster argues the budgetary worries of expanding access are overstated. Medicaid tends to pay far less than private insurers, and a typical 53% discount could drop monthly costs to $235. If 10% of eligible patients took the drugs, it would raise Medicaid spending by just 0.4%. The concerns also miss the upside. About 5 million U.S. adults use GLP1s today. If 30 million did, Goldman Sachs estimates GDP would rise as much as 0.8%. At 60 million, the increase could exceed 1%. America isn't the only country fighting this epidemic. In Britain, obesity cost the economy £31 billion a year in lower productivity, sick days and early deaths. We've created a food system that's poisoning our population and bankrupting the state, says Henry Dimbleby, co founder of Leon Restaurants, which bills itself as a purveyor of fast but healthy meals. These drugs aren't a silver bullet, but they are a bullet. Many people quit taking them within a year or two, often because of cost or gastrointestinal side effects. And lasting success still requires exercise and diet changes. But alongside those measures, GLP1s may be the key to fighting a complex disease rooted in physiology, environment and policy as much as behavior. In a society addicted to ultra processed food and sedentary hours lost in front of screens, we need new weapons. Former FDA commissioner David Kessler calls GLP1s a way to diffuse the ultra formulated food bombs that have hijacked our health. RFK Jr. Has called for lifestyle changes while cutting NIH funding the moral equivalent of telling people to lift weights while closing the gym. The administration's secretary of war, Pete Hegseth, has shamed fat generals but offers no help other than performative masculinity. Scaling access could prevent adult obesity from topping 50% and push it back toward 30%. Giving 10 million Americans GLP1s and lowering their monthly cost to $50 would run $12 billion over two years. That's a bargain. Targeting the patients most likely to benefit would improve returns further. Obesity shortens life expectancy by up to 10 years, partly because it increases the risk for more than a dozen types of cancer. Reducing its prevalence would yield massive health and productivity gains over the next 30 years. I'm sticking with the thesis I shared with Bill Maher two years ago. GLP1s will have a bigger impact on the real economy than AI OpenAI. Sam Altman calls SORA the most powerful imagination engine ever built. In reality, it's an endless feed of digital slop, further blurring the truth. The real engine of progress comes in a syringe. Maybe we should put it in the water. Researchers are aiming to preserve muscle and overcome one of the drawbacks with the first treatments or eliminate injections altogether. They're also testing GLP1s to treat conditions beyond obesity. Novo Nordisk is betting its drugs can work against Alzheimer's. Whether or not these efforts succeed, the trajectory is this technology could reverse the most expensive disease in history. America's two great growth engines are rage and carbs. AI monetizes the former, the food complex the latter. GLP1s may finally break the loop, shrinking our waistlines, cutting costs, and reminding us that progress isn't digital it's biological. The next great platform isn't the neural net it's the needle.
- [11:59]
D
Life is so rich.